Melanin-concentrating hormone receptor 1 (MCHR1) antagonists have been studied as potential agents for the treatment of obesity. Initial structure–activity relationship studies of in- house hit compound 1a and subsequent optimization studies resulted in the identification of tetrahydroisoquinoline derivative 23, 1-(2-acetyl-1, 2, 3, 4-tetrahydroisoquinolin-7-yl)-4-[4-(4- chlorophenyl) piperidin-1-yl] butan-1-one, as a potent hMCHR1 antagonist. A homology ...
